Search Results: Treatment + Ovarian Cancer (6 results)

This study tests whether COM701 (an anti‑PVRIG immunotherapy) given every 3 weeks as maintenance can delay cancer growth after a good response to platinum chemotherapy. Adults with relapsed platinum‑sensitive ovarian, fallopian tube, or primary peritoneal cancer are randomized 2:1 to COM701 or placebo.

This study is testing whether a new targeted therapy called AZD5335 works better than currently used treatments for people with platinum‑resistant ovarian, fallopian tube, or primary peritoneal cancer.The study is looking at how long people live without their cancer getting worse while taking AZD5335 compared with standard treatments. 

The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors. The study is enrolling people with BRCA1 or BRCA2 inherited mutations and have HER2-negative breast cancer, prostate cancer, pancreatic cancer, high grade ovarian, fallopian tube or primary peritoneal cancer; or other solid tumors with certain genetic mutations. 

This study is looking at whether people with ovarian cancer do better when they take the drug olaparib (also called Lynparza) for one year or for two years after finishing chemotherapy. Some participants in the study may also get another medicine called bevacizumab (Avastin) along with olaparib. You may be able to join this study if you have stage 3 or 4 ovarian cancer and either a BRCA1 or BRCA2 gene change, or a certain tumor marker called HRD.

This study will test how safe and effective the immunotherapy drug Olvi-Vec is, when it is followed by further chemotherapy and the drug bevacizumab in women diagnosed with platinum-resistant or platinum-refractory ovarian, fallopian tube or primary peritoneal cancer.

This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine.